Perioperative hyperfibrinolysis—physiology and pathophysiology
Hiperfibrinólise perioperatória — fisiologia e fisiopatologia
David Silveira Marinho
Abstract
Introduction and objectives
The role of the anesthesiologist in the perioperative management of hemostasis has attracted increasing attention. The fibrinolytic system participates in hemostasis, removing clots after repair of the vascular injury. Over the past two decades, several studies have assessed the efficacy and safety of antifibrinolytic agents in reducing perioperative bleeding and transfusion requirements. Some of the conditions that seem to benefit from antifibrinolytic drugs involve trauma, postpartum hemorrhage, cardiac surgery, spine surgery, knee or hip arthroplasty, urological and gynecological surgery, among others. However, there are currently few publications focusing on the perioperative fibrinolytic system, which will be the subject of the present review.
Content and conclusions
Fibrinolytic physiology, its relationship with the clot structure and its perioperative behavior are described. Pathophysiology mechanisms that relate to anesthesiologists and their possible perioperative scenarios are addressed according to a suggested classification. This article aims to provide anesthesiologists with a broader understanding of the normal functioning of fibrinolysis, the mechanisms of possible deviations from normality in the perioperative period, the pathophysiological rationale supporting the current indications of antifibrinolytics, and some recent outcomes obtained with their use.
Keywords
References
1 N. Mutch, N.A. Booth Plasminogen activation and regulation of fibrinolysis V.J. Marder, W.C. Aird, J.S. Bennett, S. Schulman, G.C.I. White (Eds.), Hemostasis and Thrombosis: Basic Principles and Clinical Practice (6th ed.), Lippincott Williams & Wilkins, Philadelphia, PA (2013), pp. 314-333
2 D.B. Stewart, V.J. Marder Therapy with antifibrinolytic agents V.J. Marder, W.C. Aird, J.S. Bennett, S. Schulman, G.C.I. White (Eds.), Hemostasis and Thrombosis: Basic Principles and Clinical Practice (6th ed.), Lippincott Williams & Wilkins, Philadelphia, PA (2013), pp. 918-930
3 R.M. Sniecinski, W.L. Chandler Activation of the hemostatic system during cardiopulmonary bypass Anesth Analg, 113 (2011), pp. 1319-1333
4 M. Bronisz, D. Rosc, A. Bronisz, et al. The role of intrinsic fibrinolytic system activation in pathogenesis of hemostasis disturbances in hemodialyzed patients with chronic renal failure Ren Fail, 26 (2004), pp. 223-229
5 C. Longstaff, C. Thelwell, S.C. Williams, et al. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies Blood, 117 (2011), pp. 661-668
6 M. Hoylaerts, D.C. Rijken, H.R. Lijnen, et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin J Biol Chem, 257 (1982), pp. 2912-2919
7 N. Katori, K.A. Tanaka, F. Szlam, et al. The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography Anesth Analg, 100 (2005), pp. 1781-1785
8 D. Dirkmann, K. Gorlinger, C. Gisbertz, et al. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood Anesth Analg, 114 (2012), pp. 1182-1188
9 E.A. yan, L.F. Mockros, J.W. Weisel, et al. Structural origins of fibrin clot rheology Biophys J, 77 (1999), pp. 2813-2826
10 J.P. Collet, D. Park, C. Lesty, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy Arterioscler Thromb Vasc Biol, 20 (2000), pp. 1354-1361
11 J.P. Collet, G. Montalescot, C. Lesty, et al. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis Arterioscler Thromb Vasc Biol, 21 (2001), pp. 142-148
12 C.W. Francis, V.J. Marder Physiologic regulation and pathologic disorders of fibrinolysis Hum Pathol, 18 (1987), pp. 263-274
13 A. Blanie, L. Bellamy, Y. Rhayem, et al. Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study Thromb Res, 131 (2013), pp. e6-e11
14 T.L. Chin, E.E. Moore, H.B. Moore, et al. A principal component analysis of postinjury viscoelastic assays: clotting factor depletion versus fibrinolysis Surgery, 156 (2014), pp. 570-577
15 H.B. Moore, E.E. Moore, E. Gonzalez, et al. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy J Trauma Acute Care Surg, 77 (2014), pp. 811-817
16 K. Kolev, C. Longstaff Bleeding related to disturbed fibrinolysis Br J Haematol, 175 (2016), pp. 12-23
17 J.W. Weisel, R.I. Litvinov Mechanisms of Fibrinolysis and Basic Principles of Management H.I. Saba, H.R. Roberts (Eds.), Hemostasis and thrombosis: practical guidelines in clinical management, John Wiley & Sons, Ltd, Hoboken, NJ (2014), pp. 169-185
18 G. Despotis, C. Eby, D.M. Lublin A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery Transfusion (Paris), 48 (2008), pp. 2S-30S
19 J. Kaczynski, M. Wilczynska, L. Fligelstone, et al. The pathophysiology, diagnosis and treatment of the acute coagulopathy of trauma and shock: a literature review Eur J Trauma Emerg Surg, 41 (2015), pp. 259-272
20 A. Cap, B.J. Hunt The pathogenesis of traumatic coagulopathy Anaesthesia, 70 Suppl 1 (2015), pp. 96-101
21 B.I. Eriksson, E. Hultman, S. Martinell, et al. Regional fibrinolysis following total hip replacement Thromb Res, 62 (1991), pp. 441-447
22 C.M. Bakker, H.J. Metselaar, T.N. Groenland, et al. Increased tissue-type plasminogen activator activity in orthotopic but not heterotopic liver transplantation: the role of the anhepatic period Hepatology, 16 (1992), pp. 404-408
23 H. Wada, T. Matsumoto, Y. Yamashita Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines J Intensive Care, 2 (2014), p. 15
24 S. Gando, H. Wada, J. Thachil, et al. Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS) J Thromb Haemost, 11 (2013), pp. 826-835
25 R.B. Weiskopf The use of recombinant activated coagulation factor VII for spine surgery Eur Spine J, 13 Suppl 1 (2004), pp. S83-S88
26 A. Falanga, M. Marchetti, A. Vignoli Coagulation and cancer: biological and clinical aspects J Thromb Haemost, 11 (2013), pp. 223-233
27 G.J. Caine, P.S. Stonelake, G.Y. Lip, et al. The hypercoagulable state of malignancy: pathogenesis and current debate Neoplasia, 4 (2002), pp. 465-473
28 J.I. Weitz Overview of Hemostasis and Thrombosis R. Hoffman, E.J. Benz Jr, L.E. Silberstein, H. Heslop, J.I. Weitz, J. Anastasi (Eds.), Hematology: Basic Principles and Practice (6th ed.), Saunders/Elsevier, Philadelphia, PA (2013), pp. 1774-1783
29 F. Bachmann Disorders of fibrinolysis and use of antifibrinolytic agents E. Beutler, M.A. Lichtman, B.S. Coller, T.J. Kipps, U. Seligsohn (Eds.), Williams Hematology (6th ed.), McGraw-Hill, New York (2001), pp. 1829-1840
30 H.K. Basu Fibrin degradation products in sera of women with normal menstruation and menorrhagia Br Med J, 1 (1970), pp. 74-75
31 S.C. Koh, K. Singh The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia J Thromb Haemost, 5 (2007), pp. 133-138
32 K.N. Von Kaulla, H. Kaye, E. von Kaulla, et al. Changes in blood coagulation before and after hepatectomy or liver transplantation in dogs and man Arch Surg, 92 (1966), pp. 71-79
33 H. Gans, W. Krivit Problems in hemostasis during open-heart surgery. III. Epsilon aminocaproic acid as an inhibitor of plasminogen activator activity Ann Surg, 155 (1962), pp. 268-276
34 E. Sack, T.H. Spaet, R.L. Gentile, et al. Reduction of postprostatectomy bleeding by episilon-aminocaproic acid N Engl J Med, 266 (1962), pp. 541-543
35 J. Montroy, B. Hutton, P. Moodley, et al. The efficacy and safety of topical tranexamic acid: A systematic review and meta-analysis Transfus Med Rev, 32 (2018), pp. 165-178
36 J. Wong, A. Abrishami, H. El Beheiry, et al. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial J Bone Joint Surg Am, 92 (2010), pp. 2503-2513
37 D.T. Neilipovitz, K. Murto, L. Hall, et al. A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery Anesth Analg, 93 (2001), pp. 82-87
38 N.S. Gerstein, J.K. Brierley, J. Windsor, et al. Antifibrinolytic Agents in Cardiac and Noncardiac Surgery: A Comprehensive Overview and Update J Cardiothorac Vasc Anesth, 31 (2017), pp. 2183-2205
39 K. Ker, D. Prieto-Merino, I. Roberts Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss Br J Surg, 100 (2013), pp. 1271-1279
40 A.A. Klein, P. Arnold, R.M. Bingham, et al. AAGBI guidelines: the use of blood components and their alternatives 2016 Anaesthesia, 71 (2016), pp. 829-842
41 S. Khair, I. Perelman, J. Yates, et al. Exclusion criteria and adverse events in perioperative trials of tranexamic acid in cardiac surgery: a systematic review and meta-analysis Can J Anaesth, 66 (2019), pp. 1240-1250
42 J. Yates, I. Perelman, S. Khair, et al. Exclusion criteria and adverse events in perioperative trials of tranexamic acid: a systematic review and meta-analysis Transfusion (Paris), 59 (2019), pp. 806-824
43 A.M. Sampaio, G.M.N. Guimaraes, G.P. Medeiros, et al. [Efficacy and safety of antifibrinolytics in oncological surgery: a systematic review and meta-analysis] Rev Bras Anestesiol, 69 (2019), pp. 484-492
44 P. Schoettker, C.E. Marcucci, G. Casso, et al. Revisiting transfusion safety and alternatives to transfusion Presse Med, 45 (2016), pp. e331-e340
45 CRASH-2 trial collaborators Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial Lancet, 376 (2010), pp. 23-32
46 The CRASH-3 trial collaborators Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial Lancet, 394 (2019), pp. 1713-1723
47 N. Sprigg, K. Flaherty, J.P. Appleton, et al. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial Lancet, 391 (2018), pp. 2107-2115
48 WOMAN Trial Collaborators Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial Lancet, 389 (2017), pp. 2105-2116
49 L. Sentilhes, N. Winer, E. Azria, et al. Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery N Engl J Med, 379 (2018), pp. 731-742
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email